Abareliks (Plenaxis) injektivni je antagonist gonadotropin-oslobađajućeg hormona (GnRH antagonist). On se prvenstveno koristi u onkologiji za redukivanje količine testosterona formiranog u pacijentija sa naprednom simptomatskom raka prostate za koji drugi tretmani nisu dostupni.[5][6][7][8]

Abareliks
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 183552-38-7
ATC kod L02BX01
PubChem[1][2] 16131215
DrugBank DB00106
ChemSpider[3] 10482301
ChEBI CHEBI:337298 YesY
ChEMBL[4] CHEMBL1252 YesY
Hemijski podaci
Formula C72H95ClN14O14 
Mol. masa 1416,06 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Poluvreme eliminacije 3,2 dana
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intramaskularno

ReferenceUredi

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. Drugs.com: Abarelix
  6. Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). „An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer”. Therapeutic Advances in Urology 3 (3): 127–140. DOI:10.1177/1756287211414457. PMC 3159401. PMID 21904569. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3159401/. 
  7. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3013709/.  edit
  8. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2238889/.  edit

LiteraturaUredi

Spoljašnje vezeUredi

  Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).